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Abstract 
Iron overload and chelation therapy in patients with lower risk myelodysplastic syndromes  
 
Background 
Myelodysplastic syndromes (MDS) are malignant disorders characterized by a deficient and 
disorderly hematopoiesis. The International Prognostic Scoring System divides the patients’ 
diseases into Low, Intermediate-1, Intermediate-2 and High risk. Low and Intermediate-1 are 
considered “lower risk” in clinical practice. Red cell transfusions are a common therapy for 
lower-risk MDS and therefore many patients receive a large number of transfusions during 
their disease which results in iron overload (IO). This may be treated with iron chelation 
therapy (ICT), yet the benefits in MDS patients are disputable.  
Aims 
To identify all MDS patients at Sahlgrenska University Hospital 2009-2014 that met the 
criteria for ICT and see how many of these patients actually were given ICT as well as look at 
the impact of ICT regarding transfusion dependency, S-ferritin and overall survival by 
comparing chelated and non-chelated patients. 
Methods 
Data was collected from the INCA-registry and electronic hospital journals. Our cohort was 
defined as lower risk MDS patients diagnosed or treated 2009-2014 at Sahlgrenska with end 
of 2014 as censoring date. We compared number of transfusions, S-ferritin-levels, overall 
survival and given therapy as well as other monitoring factors between chelated and non-
chelated patients. 
Results 
Sixty-nine patients were found with lower-risk MDS. Twenty-seven met the criteria for ICT 
but only nine patients had received ICT. There were no significant differences in transfusion 
dependency (P=0.883) or S-ferritin (P=0.107) between the groups. Median overall survival 
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from date of indication was 13 months longer in chelated patients (P=0.045), (23 vs 10 
months, chelated and non-chelated patients).  
Conclusions 
Our results may indicate that chelation therapy could improve survival in heavily transfused 
lower risk MDS patients as suggested in several retrospective studies, but prospective studies 
are warrented. 
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Introduction  
 
The myelodysplastic syndromes (MDS) are a heterogenic group of malignant disorders of the 
hematopoietic stem cells in the bone marrow. They are characterized by a deficient and 
disorderly hematopoiesis resulting in various degrees of cytopenias and a risk of developing 
acute myeloid leukemia (AML). The variations in symptoms and prognosis are vast. Whereas 
some patients present with profound pancytopenia and rapid progress to AML others may live 
for many years with asymptomatic anemia (1, 2). The median age at diagnosis is 75 years, 
male to female ratio is 60:40 (3).  Diagnosis is based on whole blood count, bone marrow 
morphology and chromosome karyotyping. The WHO 2008 Classification (4) divides the 
myelodysplastic disorders based on these factors as shown in the table below (Table 1).   
In addition to the WHO classification there is a scoring system known as the International 
Prognostic Scoring System (IPSS) using  the number of cytopenias (hemoglobin <100 g/L, 
ANC <1.8 x109/L, platelets <100 x109/L), the number of blasts seen in the bone marrow as 
well as karyotype to estimate the risk score (5). This estimates the prognosis of a specific 
patient (see Table 2).  With the IPSS score the conditions are divided into Low, Intermediate-
1 (INT-1), Intermediate-2 (INT-2) and High risk MDS. In clinical practice the terms “lower 
risk” meaning IPSS Low risk and INT-1, and “higher risk” meaning IPSS INT-2 and High 
risk are used.  
 
The Revised International Prognostic Scoring System (IPSS-R) was introduced in 2012 (6). 
This was an update of the previous IPSS system where several different clinical features in 
such as patient age, number of blasts down to two percent and a more thorough separation of 
the cytogenetic differences were added to the classification. We have chosen to use the IPSS 
system since The R-IPSS were introduced in 2012, and our cohort is from 2009-14. 
 The primary therapy for lower risk MDS patients is erythropoiesis-stimulating agents (ESA) 
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and/or Granylocyte colony stimulating factor (G-CSF) (1, 2). If the response to ESA/G-CSF 
is inadequate, the next step in therapy is regular transfusions (2). For patients with hypoplastic 
MDS, immunosuppressive therapy can be an option. For higher risk MDS therapeutic choices 
include hypomethylating agents (e.g. azacytidine) and low-dose chemotherapy (1). The only 
curable treatment is allogeneic transplantation, being an option for patients <70 years and 
higher risk MDS.  
 
Treatment with ESA can improve anemia with an effect lasting on average two years (range 
3-118 months) (7). Most patients with MDS will eventually require red cell transfusions (8). 
The many red cell transfusions given to these patients result in iron overload mainly attributed 
to reticulo-endothelial iron recycling (8) which causes an accumulation of iron in the tissue 
and results in damages mainly to the heart, liver and endocrine glands of the body (9, 10). 
Iron overload and its consequences is more thoroughly studied in thalassemia patients where 
studies have shown that iron overload can result in cardiomyopathy, liver cirrhosis, 
hypogonadism, hypothyroidism, diabetes due to iron deposition in the beta cells of the 
pancreas etc. (11-13). Iron chelation therapy allows us to chemically remove the iron from the 
body (14). Studies have shown that we can prolong the patient’s life and prevent organ 
complications with the use of iron chelation therapy (11, 13, 15). Hematologists today use this 
knowledge in the treatment of MDS (16-18). 
 
The MDS Guideline Programme (2) states that only patients where long term transfusion 
therapy is likely are to be considered for iron chelation. For patients with refractory anemia 
(RA), refractory anemia with ring sideroblasts (RARS) and MDS associated with isolation 
deletion (5q-) iron chelation therapy is indicated unless the patient is of very high age or has 
severe concomitant disease. When it comes to refractory anemia with multilineage dysplasia 
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(RCMD) and more advanced MDS iron chelation should only be considered for patients with 
a life expectancy of at least 2 years from the time point where iron overload is reached. It is 
also recommended to chelate patients that are eligible for allogeneic stem cell transplantation 
(SCT).  Iron chelation is recommended to start when S-ferritin exceeds 1500 µg/L or after 
approximately 25 red cell transfusions. 
 
Seeing as the MDS population is elderly echocardiography is used in the monitoring of heart 
function, in both elderly and iron overloaded patients, to detect signs of congestive heart 
failure or other cardiac effects (5, 11, 13, 19) . Cardiovascular T2-star magnetic resonance 
imaging (MRI) MRT2 * imaging can be used to monitor cardiac and liver iron overload (20, 
21). 
 
Today, we have three different drugs available for the treatment of iron overload; Deferiprone 
(Ferriprox®), Deferoxamine (Desferal®) and Deferasirox (Exjade®). All the drugs have 
disadvantages, either because of side effects or because of way of administration (22). As 
mentioned above active chelation therapy can prolong a prolong the patient’s life and prevent 
organ complications (15). For grown MDS-patients, however, we know (23) that many 
patients are iron overloaded without being chelated even though recent studies have indicated 
that there may be a survival advantage for MDS patients treated with iron chelation therapy 
(17, 18).  
 
Transfusion dependency plays an important role in prognostics and overall survival in MDS 
why we have chosen to look specifically at this in our study. The higher number of 
transfusions per month; the worse the prognosis (24). These discoveries have resulted in an 
updated prognosis scoring system - the WPSS, which takes transfusion dependency into 
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consideration which the IPSS system does not (25). S-Ferritin levels are commonly used in 
the monitoring of potential iron overload (17, 23, 26) and recommended for this purpose (1, 2, 
27).  
 
Specific objectives   
 
 
Our hypothesis is that transfusion dependent patients with lower risk MDS and iron overload 
are undertreated with chelating agents, due to rather unclear directions as to who shall receive 
this, and drugs that have many side effects.  
Our specific aims were to: 
 Identify all patients diagnosed and/or treated 2009-2014 at Sahlgrenska University 
Hospital with lower risk MDS.  
 Identify how many patients in this population meet the criteria for iron chelation 
therapy.  
 Identify how many patients that actually are given iron chelation therapy.  
 Investigate how patients with and without chelation therapy were followed up.  
 Investigate if there was any benefit in terms of transfusion dependency, S-ferritin and 
overall survival in the chelated patients compared to the patients that did not receive 
chelation therapy. 
 
Material and Methods  
 
Patients 
All patients registered in the INCA-registry (Information Network for Cancer in Sweden) who 
were diagnosed with Myelodysplastic syndromes (MDS) at the Department of Hematology, 
Sahlgrenska University Hospital during 2009 and 2014 was the source of eligible patients for 
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the study. As chelation treatment mostly is used in patients with lower risk MDS, i.e. patients 
with an IPSS score of up to 1 point (Low and INT-1) (2), we defined our cohort to be lower 
risk MDS patients with a follow-up-time up to Dec 31st, 2014.   
 
Data collecting procedures 
Age, gender, date of MDS diagnosis, date of death and prognostic score for the patients was 
gathered from the INCA MDS registry.  The patients’ electronic journals from Melior were 
the source of information about treatment, and blood values were read from the LabBest or 
FlexLab system. Serum-ferritin-levels were recorded at least once a year, if possible. The 
different types of therapy which the patients had been given for their MDS were registered. 
The different therapies were divided into groups; erythropoiesis stimulating agents (ESAs), 
Granulocyte – colony stimulating factors (G-CSF), immunosuppressive therapy (e.g. 
cortisone, cyclosporine, TNFα-inhibitors etc.), chemotherapy, azacytidine, red cell 
transfusions and iron chelation therapy. The number of months on therapy was recorded, as 
well as number of transfusions. Some patients underwent allogeneic SCT and the date of 
transplantation was registered.  
 
According to the MDS Guideline Programme (2), the date when the patients reached either a 
level of S-ferritin of 1500 µg/L or had received  25 red cell transfusions was defined as the 
date when iron chelation was indicated. These factors were examined for all patients and the 
dates of indication were recorded for the patients who met the criteria regarding S-ferritin 
and/or number of transfusions. In this manner, two groups were created and studied closer 
(Table 3), both those who received chelation and those who fulfilled the criteria, but did not 
receive chelation. The patients who did not meet the above mentioned criteria or did not 
receive chelation therapy were not targets for further investigation.  
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The date of initiation of chelation therapy was recorded or date when the patients met the 
criteria of chelation therapy indication as mentioned above, referred to as date of indication. 
For the chelated patients, the time (in months) on chelation therapy was recorded. Endpoints 
were set as time of death or December 31st 2014 as censoring date for the patients still alive.  
 
In order to see if the number of transfusions decreased after initiation of chelation therapy, the 
number of transfusions given during the three months prior to either initiation of chelation 
therapy or to the date of indication as mentioned above was compared to transfusion 
dependency during the six months following after initiation of chelation or date of indication. 
The total number of transfusion given from diagnosis to death or censoring date was recorded 
for all patients. 
 
The Serum-ferritin (S-ferritin) was used as a marker for iron overload. For both chelated and 
non-chelated patients the S-ferritin level was recorded at time for start of chelation or the time 
that the criteria for chelation were fulfilled and as close to six months later as possible in 
order to see if the chelation therapy had any impact on the S-ferritin level. In the cases where 
there were no S-ferritin samples taken within six months of the desired time points no S-
ferritin levels were recorded.   
 
Additional indicators of iron overload were elevated liver transaminases (S-ALT and S-AST). 
A doubling of the upper limit of reference range was considered to be pathological for liver 
transaminases i.e. S-ALT ≥1.5 µg/L and S-AST ≥ 1.2 µg/L according to the reference ranges 
of the Sahlgrenska University Hospital laboratory.  We also wanted to see how many patients 
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that had performed echocardiography in order to finds signs of congestive heart failure 
recorded as reduced left ventricular ejection fraction (LVEF). 
 
Mean and median survival date of reached indication for the chelation and non-chelation 
group were obtained respectively and the groups were compared. Survival from diagnosis for 
all patients was recorded.  
 
Statistical methods 
To examine significance in the differences in transfusion dependency for the two groups 
between the two time points Independent-Samples T-test was performed. This method was 
also used to examine the differences in S-ferritin for the two time points. To depict survival 
the Kaplan-Meier method was used and the Log Rank/Mantel-Cox test was used to examine 
the significance of the difference between the Kaplan Meier curves. The Cox regression 
analysis for the factor Treatment i.e. chelation vs non-chelation was used to further examine 
the differences in survival. Seeing as our material was rather small a 4x4 crosstab was created 
regarding occurrence of events and the Fisher’s exact test was performed to examine the 
statistical significance between the two groups. All statistical analyses were performed in 
IBM SPSS Statistics 22. 
 
Ethics  
 
This project was a student project and considered a work of improvement; hence it was not 
necessary for us to apply for admission from the ethical board. The project required us to read 
the medical records of living as well as deceased patients. When doing so we used methods to 
keep the confidentiality of the patients by unidentifying them as well as keeping all 
documents regarding their data in encrypted files with password protection.  
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Results  
   
Patients 
In total 169 patients diagnosed with MDS were found in the INCA registry from Sahlgrenska 
University hospital in the period 2009-14.  After the exclusion of 100 patients due to different 
(Table3), 69 patients were eligible as the study population.   
Twenty-seven out of 69 patients fulfilled the criteria for receiving chelation therapy i.e. 
received at least 25 red cell transfusions and/or having a S-ferritin of at least 1500 µg/L. Out 
of these 27 patients there were nine patients who actually had been given chelation therapy 
(chelated group) while the remaining 18 patients never had received chelation therapy (non-
chelated group).   
 
The median age of the patients in the chelated group was 72 years at diagnosis compared to 
75 years in the non-chelated group (see Table 4). There was also a larger fraction of patients 
with Low IPSS (=IPSS score 0) in the chelated group, three out of nine patients (33 percent) 
compared to four out of 18 patients (22 percent) in the non-chelated group.   
 
When comparing the different regimes of treatment in the two groups it was evident that the 
group which eventually received chelation therapy were more often given ESAs, G-CSF, 
Azacytidine as well as immunosuppressive therapy (Table 4). Four patients in the non-
chelated group underwent allogeneic SCT due to transformation to AML whereas no patient 
in the chelated group was transplanted. 
 
Transfusions 
Figures 1a and 1b depict the transfusion dependency over time in the two groups. The mean 
difference in transfusions between three months prior to start of chelation and six months after 
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was an increase in 0.4 transfused units per months, (median 0.3 transfused units per month) in 
the chelated group compared to a mean difference of 0.2 transfused units per month (median 0 
transfusions per month) in the non-chelated group.  
Thereby transfusion dependency increased over time in both groups but the difference 
between the groups was not statistically significant (P=0.883). 
 
Ferritin levels 
The levels of ferritin decreased clearly in the chelated group (see Figure 2a) with a mean 
difference of approximately -980 µg/L between the start of chelation therapy and six months 
later. The median level of ferritin at the first measurement was 3400 µg/L and 2100 µg/L at 
the second measurement. We could also see that the inter-individual variance was large and 
could also see that there was a trend towards aggregation at a level close to the 1500 µg/L 
which is the level where chelation therapy is indicated. A majority (five out of nine patients) 
ended up with a ferritin level between 1100 and 2100 µg/L.   
 
As for the non-chelated group we noticed that the follow-up of S-ferritin was not as thorough.  
Out of the entire group of 18 patients, only six patients had S-ferritin levels monitored 
relatively close to the date of reached indication and six months later. We have chosen to only 
include these six patients in the tables regarding this (Figure 2b). The mean difference 
between the two time points was an increase of approximately 480 µg/L of ferritin. The 
median level of ferritin at the first measurement was 1650 µg/L and 1900 µg/L at the second 
measurement. Although the figures show a clear difference in this small sample there was no 
statistical significance between the groups (P=0.107). 
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Monitoring of iron overload in liver and heart  
Regarding the additional monitoring of iron overload all chelated patients had undergone 
examination of liver transaminases and six out of nine patients had undergone 
echocardiography. None of these patients showed signs of congestive heart failure.  Eight of 
nine patients (89 percent) had elevated levels of ALT or both ALT and AST at least once 
from MDS diagnosis. In the non-chelated group, 16 out of 18 patients (89 percent) had 
undergone examination of liver transaminases and in 9 out of 18 patients (50 percent) 
echocardiography was performed. Eight patients had elevated levels of ALT or ALT and AST 
at least once from MDS diagnosis. One patient had congestive heart failure in this group, but 
this was due to aortic stenosis and not to iron overload. No patient was examined with MRI 
T2* in order to evaluate iron overload. 
  
Survival 
The overall survival seemed to be better in the chelated group. The median total duration of 
illness (survival time from diagnosis) was approximately 46 months in the chelated group 
(mean 42 months) as compared to approximately 30 months (mean 30 months) in the non-
chelated group. We examined the difference between the two groups by comparing survival 
from date of reached indication in both groups. This resulted in a median survival of 
approximately 23 months (mean 29 months) in the chelation group compared to 10 months in 
the non-chelated group (mean 12 months). The data also shows that a majority (five out of 
nine) of the chelated patients were still alive at the end of study. 
  
The Kaplan-Meier curve (Figure 3) showed a statistically significant difference between the 
two groups, (P=0.045). The Cox regression analysis for difference between the groups was 
borderline significant, P=0.058.   
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Discussion 
 
We have studied patients diagnosed with low risk MDS, identified the population that 
fullfilled the criteria for iron chelation due to iron overload and compared patients that did or 
did not receive chelation therapy. 
 
Generally, we can say that no statistical significance between the groups was seen in the 
differences in both transfusion dependency and S-ferritin but there was a clear difference in 
overall survival. This could be a result of several different factors, such as age, co-
morbidities, more aggressive disease but may also be a result of inadequate therapy in the 
non-chelated group. 
 
The patients in the chelated group were given more treatment for their MDS disease, with 
higher numbers of patients treated with the first line of therapy; ESA and G-CSF. The 
chelated group was also given azacytidine and immunosuppressive treatment to a greater 
extent than the non-chelated group. The fact that more patients in the non-chelated group were 
given chemotherapy and underwent SCT (no patient in the chelated group) was mainly due to 
transformation into acute myeloid leukemia (AML), indicating that this patient group, 
although regarded as lower risk patients, had a more aggressive disease. This occurred in five 
patients (28 percent) in the non-chelated group whereas only one patient transformed to AML 
in the chelated group. We are uncertain why this was the case but it has previously been 
suggested that chelation therapy reduces the risk of MDS progression to AML (28) and 
studies on cell lines have also showed that chelation therapy could have anti-proliferative 
effects on several different cell-lines including myeloid cell-lines (29, 30) as well as 
potentiate anti-neoplastic activity in cells (31).  
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Regarding transfusion dependency, we saw that both groups increased their average number 
of transfusions per month between the two time points of investigation as mentioned above. 
There was no statistical significance between the groups (P=0.883, not significant) hence we 
cannot draw any conclusions regarding transfusion dependency in this study. We see, though, 
in actual figures that the mean number of transfusions given per month was higher at both 
time points in the non-chelated group. This may have had an impact on the overall survival of 
the groups as transfusion dependency is clearly viewed as a prognostic factor for overall 
survival (17, 24, 25) and is taken into consideration in the WPSS scoring system as mentioned 
above (25).  
 
When examining the difference in S-ferritin it was obvious that the monitoring of the non-
chelated patients was not as thorough as for the chelated patients. Only six out of 18 patients 
had ferritin samples that we could analyze in this way even though these patients had been 
given at least 25 red cell transfusions or had S-ferritin-levels over 1500 µg/L. This is not 
unusual, at least one previous study has shown the same pattern (17).  
 
We could see that the S-ferritin levels decreased in the chelated group (mean decrease 980 
µg/L) whereas the ferritin levels increased in the non-chelated group (mean increase 480 
µg/L). Previous retrospective studies have shown no decrease in ferritin after start of chelation 
therapy (32) yet interventional trials have shown significant reductions in ferritin (33, 34) why 
it is difficult for us to draw any conclusions on our own results. The results in our study are 
not statistically significant (P=0.107) but we might interpret the results as a trend towards a 
better effect of decreasing ferritin levels with chelation therapy, at least in this study.  
 
Additional markers of iron overload as liver transaminases and echocardiography were also 
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more closely monitored in the chelated group. A higher percentage of the chelated patients 
had elevated transaminases during some point in the course of the disease which could 
indicate a higher degree of iron overload. This pattern could also be seen in the generally 
higher S-ferritin levels of the chelated group (Figures 2a and 2b). As mentioned above only 
one patient showed pathologic values of ejection fraction which was attributed to stenosis of 
the aortic valve and not due to iron overload.  
 
The survival from date of indication for both groups was compared i.e. different time points 
than the other factors. The median difference between the groups was approximately 13 
months (P=0.045, see Figure 3). The median age of the patients in the chelated group was 
higher than in the non-chelated group. We interpreted the fact that a majority of the chelated 
patients still alive at the end of the study a positive prognostic factor too. Age has been shown 
to have an effect on overall survival in several studies and especially in the patients with 
lower risk MDS (24, 25). The larger fraction of patients with a “Low IPSS score” in the 
chelated group could also have an impact on the better overall survival in this group.  
 
Since we have not adjusted for age, IPSS and co-morbidities in the study we can only 
consider our results as an indication that chelation therapy may prolong survival in heavily 
transfused MDS patients, similar to the results of several recent studies that have suggested 
that chelation therapy can be regarded as an independent positive prognostic factor for overall 
survival in heavily transfused MDS patients (17, 23, 32, 35).  
 
One very possible bias in this study is the clinicians’ decision of treatment and potential 
chelation therapy might be that the clinicians decide on beforehand which patients they 
believe have better chance of survival and therefore choose therapy (first line, second line etc. 
  
 18 
 
and eventually also chelation therapy) with this taken into consideration. This possible bias 
has also been discussed in other previous articles (17, 23).  
 
Another general observation is that only a portion of the patients eligible for chelation have 
been given chelation therapy. We consider this due to elderly patients, expensive drugs, the 
known side effects as well as vague guidelines. Another interesting remark is that two of the 
non-chelated patients had a clear iron overload at the time point of their stem cell transplant 
even though the MDS Guideline Programme states that iron overload should be avoided in 
candidates for stem cell transplant and therefore iron chelation therapy should be considered 
to prevent iron overload in these patients (2).  
 
One clear weakness with our study is of course the limited material and amount of patients 
included as well as the lack of multivariate analysis including e.g. adjustment for age and co-
morbidities. Another weakness is the use of different time points when comparing different 
factors. On the other hand, one of the strengths of the study is that seeing as the study 
population was rather small we have been able to follow every patient’s course of disease 
closely, and have had time to scrutinize the patients’ electronic journals. Thereby we have 
been able to extract many different factors and information regarding each patient. 
 
Conclusions and Implications 
 
Regarding transfusion dependency we could not see any significant benefits with chelation 
therapy. Regarding overall survival we believe our results may indicate that chelation therapy 
could be beneficial for heavily transfused MDS patients as it has been suggested in several 
recent retrospective studies. One randomized study presented at ASH 2015 (The 57th 
American Society of Hematology Annual Meeting and Exposition) (36) indicates that 
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chelation can be beneficial to patients with lower risk MDS regarding survival, but further 
randomized studies are warranted. 
 
In conclusion, we want to illuminate the need of clearer guidelines regarding iron chelation 
therapy seeing as many patients at our clinic have not been given chelating agents even 
though several studies have shown improved survival as well as other benefits with this 
treatment.  
 
 
Populärvetenskaplig sammanfattning på svenska 
 
Järninlagring och kelatbehandling hos patienter med lågrisk myelodysplastiskt 
syndrom 
 
Myelodysplastiskt syndrom (MDS) är en grupp blodsjukdomar som kännetecknas av att 
benmärgen tappar förmågan att tillverka röda blodkroppar, vita blodkroppar eller blodplättar 
på rätt sätt. Detta gör att patienterna dels får blodbrist (anemi) och därmed får svårare att 
transportera syre, dels får svårt att tackla eventuella infektioner alternativt blir 
blödningsbenägna. Utifrån en rad variabler, bl a blodvärden, genetiska förändringar och 
förekomst av omogna celler delar man in sjukdomarna in i ”lägre risk” och ”högre risk” (för 
övergång i akut leukemi eller att avlida av sjukdomen). För patienter med lågrisk MDS består 
behandlingen ofta i blodtransfusioner  (blodöverföring) för att höja blodvärdet. Många 
blodtransfusioner innebär risken att man även får för mycket järn som kroppens celler lagrar 
in vilket kan ge komplikationer såsom hjärt- och leversvikt.  
 
Så kallad  kelatbehandling/kelering kan användas för att ta bort järnet ur kroppen. Järnet binds 
genom en kemisk reaktion och skiljs ut genom urin eller avföring. Tyvärr finns inga bra 
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studier för denna patientgrupp som har visat att kelatbehandling hjälper, däremot finns studier 
för andra grupper av patienter med anemi sedan födseln där behandlingen har god effekt. 
Kelatbehandling rekommenderas därför till patienter som får regelbundna blodtransfusioner, 
har höga ferritin-värden (”depåjärn”) och som dessutom förväntas leva mer än två år. 
Läkemedlen är dyra och kan ha svåra biverkningar varför vissa läkare drar sig för att använda 
dem.  
 
I denna studie granskades journaler från alla patienter som passerat Sahlgrenskas 
hematologiska öppenvård under 2009-2014. Totalt 27 patienter hade antingen fått så mycket 
blod eller hade så pass höga ferritin-värden att de uppnådde gränsen för att få kelatbehandling. 
Av dessa hade slutligen nio patienter fått behandlingen. 
 
Mängden mottagna blodpåsar samt patienternas ferritin-värden jämfördes med samma värden 
för den grupp med 18 patienter som enligt riktlinjerna borde fått kelatbehandlingen men som 
av olika skäl inte fick den. Några statistiskt säkerställda skillnader mellan mängden givet blod 
kunde inte ses, däremot sågs en trend mot att de patienter som fick kelatbehandling fick lägre 
ferritin-värden medan övriga patienter istället fick högre värden av ferritin under motsvarande 
period.  Överlevnaden jämfördes mellan grupperna och man konstaterade att patienterna som 
fick kelering levde i genomsnitt 13 månader längre än de patienter som inte fick 
behandlingen. 
 
Patienterna med kelatbehandling blev dessutom mer noggrant övervakade vilket skulle kunna 
vara en fingervisning om att läkarna på förhand, medvetet eller omedvetet, väljer ut vilka 
patienter som skall ”satsas på”.  
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Mängden patienter i studien är liten varför man ej kan dra stora slutsatser av resultaten. 
Vidare har det ej justerats för ålder och samsjuklighet vid jämförelse av överlevnad mellan 
grupperna. En styrka med studien är dock att man kunnat granska varje enskild individ i 
studien noggrant. 
 
Resultaten från studien går i linje med från tidigare studier som tyder på en överlevnadsfördel 
med kelatbehandling men för att fastställa detta krävs större s.k. prospektiva, dvs 
framåtblickande studier.  
 
Studien visar att för få patienter mellan 2009 och 2014 har fått kelatbehandling och att det 
därför behövs tydligare riktlinjer då dagens riktlinjer inte verkar räcka till för att alla ska få 
den behandling de behöver.  
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Tables and Figures 
 
Table 1, The WHO 2008 Classification of Myelodysplastic syndromes  
 
 
Myelodysplastic syndromes: 
“Lower risk”: 
Refractory anemia (RA)  
Refractory neutropenia (RN)  
Refractory thrombocytopenia (RT)  
Refractory anemia with ring sideroblasts (RARS) 
Refractory anemia with multilineage dysplasia (RCMD) 
MDS associated with isolation deletion (5q-) 
“Higher risk”: 
Myelodysplastic syndrome – unclassified (MDS-U) 
Refractory anemia with excess blasts-1 (RAEB-1) 
Refractory anemia with excess blasts-2 (RAEB-2) 
Mixed MDS/MPN: 
Chronic myelomonocytic leukaemia (CMML) 
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Table 2, IPSS-score  
 
The table describes how to calculated the IPSS-score which is the most commonly used 
scoring system for prognostics regarding Myelodysplastic Syndromes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: IPSS, International Prognostics Scoring System; BM, Bone marrow; ANC, absolute neutrophil 
count; INT-1, Intermediate-1; INT-2, Intermediate-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Atypical chronic myeloid leukaemia, BCR-ABL1 negative (aCML) 
Juvenile myelomonocytic leukaemia (JMML) 
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN) 
Refractory anaemia with ring sideroblasts associated with marked 
thrombocytosis (RARS-T) (provisional entity)2  
Prognostic Variable 
 
Score Value 
 0 0.5 1.0 1.5 2.0 
BM blasts (%) <5 5-10 — 
11-
20 
21-30 
Karyotype* Good Intermediate Poor   
Cytopenias¤ 0/1 2/3    
 *Good:normal,-Y,del(5q),del(20q). Poor: complex (>3 abnormalities) or 
chromosome 7 anomalies. Intermediate: other abnormalities. ¤Hemoglobin 
<100 g/l, ANC <1.5 x 109/l, platelets <100 x 109/l. 
 
Scores for risk groups are as follows: Low, 0; INT-1, 0.5-1.0; INT-2, 1.5-2.0; 
and High, ≥2.5. 
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Table 3, Patient Selection 
 
The number of patients with MDS at Sahlgrenska 2009-2014, as well as the number of 
patients excluded from the study for each of the following reasons as shown in the left 
column, generating the study population. 
 
 No of patients 
All patients with MDS at Sahlgrenska 2009-14 
according to the INCA-MDS-registry:  
169 
No IPSS available :  
 
13 
IPSS  1.5:  
 
42 
MDS/MPN: 
 
30  
Secondary MDS: 
 
3 
Treated outside the region:  
 
3 
Severe comorbidities: 2 
other malignacies: 
 
2 
not fulfilling MDS criteria:  
 
4 
 
non-correlating transfusions and S-ferritin : 
 
1 
Patients theoretically eligible for chelation 
therapy: 
69 
 
Abbreviations: INCA, Informationsnätverk för cancervården (Information Network for Cancer Care); MDS, 
Myelodysplastic Syndrome; IPSS, International Prognostic Scoring System; MDS/MPN, Mixed Myelodysplastic 
Syndromes/Myeloproliferative Neoplasms 
 
 
Table 4, Demographics, diagnosis, IPSS-score and therapy 
 
Presentation of the variations in demographics, diagnosis, IPSS-score and therapy for the 27 
patients who met the criteria for receiving chelation therapy and hence studied closer in the 
study. 
 
  All pts 
N=27 
% Chelated 
N=9 
% Non-chelated 
N=18 
% 
Age  Mean 70.5  72  69.5  
 Median 75  72  75  
 range 17-91  60-83  17-91  
Gender male 20 74.1 6 66.7 14 77.8 
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 female 7 25.9 3 33.3 4 22.2 
        
Diagnosis RA 1 3.7 0 0 1 5.6 
 RARS 2 7.4 1 11.1 1 5.6 
 RCMD 19 70.4 6 66.7 13 72.2 
 5q- 3 11.1 1 11.1 2 11.1 
 MDS-U 2 7.4 1 11.1 1 5.6 
 RAEB-1 0 0 0 0 0 0 
 RAEB-2 1 3.7 0 0 1 5.6 
        
IPSS Low 7 25.9 3 33.3 4 22.2 
 Int-1 20 74.1 6 66.7 14 77.8 
        
Therapy ESA  10 37.0 6 66.7 4 22.2 
 G-CSF 9 33.3 6 66.7 3 16.7 
 Transfusions  27 100 9 100 18 100 
 Chelation 9 33.3 9 100 0 0 
 Azacytidine 5 18.5 2 22.2 3 16.7 
 Immunosuppressive 
therapy 
12 44.4 5 55.6 7 38.9 
        
 Chemotherapy 10 37.0 3 33.3 7 38.9 
 Stem cell transplant 4 14.8 0 0 4 22.2 
 
Abreviations: RA, Refractory anemia; RARS, Refractory anemia with ring-sideroblasts; RCMD, Refractory 
cytopenia with multilineage dysplasia; 5q-, Myelodysplastic syndrome associated with isolated del(5q); MDS-U, 
Myelodysplastic syndrome, unclassifiable; RAEB-1, Refractory anemia with excess blasts 1; RAEB-2, 
Refractory anemia with excess blasts 2; ESA, Erythrpoietin stimulating agents; G-CSF, Granylocyte-colony 
stimulating factor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a 
Transfusion dependency before and after  
chelation therapy, chelated patients 
Figure 1b 
Transfusion dependency before and after 
reached indication, non-chelated patients
 
 
Fig 1a Transfusion dependency (mean number of transfusions given per month) shown for the chelated patients. 
The mean difference between the three months prior to start of chelation therapy and the six months following 
after start of chelation therapy was an increase in 0.3 red cell transfusions per month (median 0.4). The figure 
displays the individual variance between the two time periods.  
Fig 1b Transfusion dependency shown for the non-chelated patients. The mean difference between the three 
months prior to the date when each patient reached the indication for chelation therapy (in our study when the 
patient reached 25 red cell transfusions or had a S-ferritin of at least 1500 µg/L) and the six months following the 
date of reached indication was 0.2 months (median 0). When comparing the mean difference between the two 
groups (chelated and non-chelated patients) there was no statistical significance (P=0.883). 
 
 
 
Figure 2a  
Ferritin levels before and after chelation, 
chelated patients. 
 
   
Figure 2b 
Ferritin levels before and after date of 
reached indication, non-chelated patients 
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Fig 2a Ferritin levels before and after initiation of chelated therapy shown for the chelated patients. There as a 
mean decrease in ferritin levels of 980 µg/L between the start of chelation therapy and six months later. No 
statistical significance was seen between the groups (P=0.107).  
Fig 2b Ferritin levels before and after date of reached indication for chelation therapy for the non-chelated 
patients. Only six of the non-chelated patients had ferritin values that from the examined time points. In these six 
patients there was a mean increase in ferritin levels of 480 µg/L between the time point where they should have 
been offered chelation therapy (according to the guidelines) i.e. date of reached indication for chelation therapy, 
and six months later. No statistical differences was seen between the groups (P=0.107). 
 
 
 
Figure 3, Cumulative survival displayed as Kaplan-Meier curve 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3 The Kaplan-Meier curve depicts the difference in cumulative survival from the date of reached indication 
(for chelation therapy) between the chelated and the non-chelated patients. The median time between date of 
reached indication to death or end of study was 23 months for the chelated patients. As for the non-chelated 
patients the median time between the date of reached indication and death or end of study was only 10 months. 
The Log Rank (Mantel-Cox) value shows that the differences were statistically significant (P=0.045).  
 
 
Overall comparisons 
 
Chi-
Square df Sig. 
Log Rank 
(Mantel-Cox) 
4.025 1 .045 
Breslow 
(Generalized 
Wilcoxon) 
5.375 1 .020 
Tarone-Ware 4.892 1 .027 
